Anticonvulsants Market Report 2026

The anticonvulsants market size has grown steadily in recent years. It will grow from $19.25 billion in 2025 to $19.89 billion in 2026 at a compound annual growth rate (CAGR) of 3.3%. The growth in the historic period can be attributed to rising prevalence of epilepsy, increasing awareness about nerve pain, limited generic anticonvulsant availability, advancements in neuropharmacology, government healthcare initiatives.

The anticonvulsants market size is expected to see steady growth in the next few years. It will grow to $23.4 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, growth in geriatric population, expansion of outpatient care facilities, rise in R&D for combination therapies, digital health integration in epilepsy management. Major trends in the forecast period include personalized anticonvulsant therapy, development of novel drug delivery systems, growth in geriatric epilepsy population, expansion of outpatient neurology services, increasing use of combination therapies.

The increasing prevalence of epilepsy is anticipated to drive the expansion of the anticonvulsants market in the coming years. Epilepsy is a widespread neurological disorder that affects the brain and is often characterized by recurrent seizures. It is a chronic, non-communicable brain disease that impacts individuals across all age groups. Anticonvulsants are drugs prescribed to reduce or suppress seizure activity in people living with epilepsy. These medications help manage epilepsy symptoms by inhibiting abnormal electrical signals in the brain that trigger seizures, although they do not necessarily cure the condition. For example, in February 2023, the World Health Organization, a Switzerland-based United Nations public health agency, reported that approximately 5 million people worldwide are diagnosed with epilepsy each year. High-income countries record an estimated 49 new epilepsy cases per 0.1 million people annually, while low- and middle-income countries report as many as 139 cases per 0.1 million people. As a result, the growing prevalence of epilepsy is contributing to the growth of the anticonvulsants market.

Key companies operating in the anticonvulsants market are prioritizing the development of innovative drug therapies and obtaining regulatory approvals to address unmet needs in seizure control and reinforce their market position. New anticonvulsant treatments are designed to improve therapeutic outcomes for patients experiencing seizures linked to rare and severe neurological disorders. For instance, in March 2024, the Medicines and Healthcare products Regulatory Agency, the UK’s national regulatory authority, approved ganaxolone (Ztalmy) as the first anti-seizure medication indicated for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Ganaxolone, a neuroactive steroid, offers a new treatment option for this complex epileptic encephalopathy by targeting difficult-to-manage seizures and addressing a significant unmet clinical need for affected patients.

In January 2023, Catalyst Pharmaceuticals, a US-based commercial-stage biopharmaceutical company, acquired the US rights to FYCOMPA (perampanel) CIII from Eisai Co. Ltd for an undisclosed sum. This acquisition of FYCOMPA (perampanel) was intended to strategically strengthen the company’s neurology portfolio, with a particular emphasis on epilepsy treatment. FYCOMPA (perampanel) CIII is a prescription medication used in the management of epilepsy, specifically for patients with partial-onset seizures. Eisai Co. Ltd is a Japan-based pharmaceutical company engaged in the manufacture of anticonvulsant medications.

Major companies operating in the anticonvulsants market are Eisai Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, Jazz Pharmaceuticals Inc., UCB SA, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Sanofi SA, Zydus Lifesciences Ltd., Lupin Limited, Ratiopharm Group, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Laurus Labs Limited, Recordati S.p.A., Neurocrine Biosciences Inc.

North America was the largest region in the anticonvulsants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global anticonvulsants market report during the forecast period. The regions covered in the anticonvulsants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anticonvulsants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the anticonvulsants market by increasing the cost of imported raw materials, active pharmaceutical ingredients, and specialized drug delivery equipment. The rise in production costs has primarily affected high-volume segments such as tablets and capsules, with regions like North America and Europe experiencing the highest impact. While these tariffs have caused supply chain delays and increased prices, they have also encouraged local manufacturing investments and innovation in cost-efficient production methods, providing a positive push for regional pharmaceutical players.

The anticonvulsants market research report is one of a series of new reports that provides anticonvulsants market statistics, including anticonvulsants industry global market size, regional shares, competitors with a anticonvulsants market share, detailed anticonvulsants market segments, market trends and opportunities, and any further data you may need to thrive in the anticonvulsants industry. This anticonvulsants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anticonvulsants, also known as anti-seizure medications or antiepileptics, are drugs used to prevent and manage seizures or convulsions by regulating abnormal electrical activity in the brain. These medications are also prescribed for conditions such as nerve pain and restless leg syndrome.

The primary types of anticonvulsants include pyrimidinediones, fructose derivatives, aromatic allylic alcohols, valproylamides, carboxamides, bromides, and others. Pyrimidine is a heterocyclic aromatic organic compound that forms a structural component of nucleic acids such as DNA and RNA, as well as certain proteins, starches, and others. These drugs are developed across first-generation, second-generation, and third-generation categories and are available in dosage forms such as capsules, tablets, liquids, rectal gels, and others. They are used for applications including migraine, epilepsy, neuropathic pain, anxiety, fibromyalgia, bipolar disorder, and borderline personality disorder, and are utilized by end users such as hospitals, clinics, and others.

The anticonvulsant market consists of sales of drugs such as phenobarbital, phenytoin, carbamazepine, levetiracetam, ethosuximide, clonazepam, diazepam, lorazepam, and midazolam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.